MedinCell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 19th, 2023
11 Dicembre 2023 - 6:00PM
Business Wire
Regulatory News:
MedinCell, Euronext: MEDCL (Paris:MEDCL):
MedinCell will hold a videoconference
on Tuesday December 19th, 2023 at 6:30 pm to present the half-year
financial results (April 2023-September 2023)
> To watch the meeting in
French: https://www.medincell.com/fr/investisseurs/#events_
> To watch the meeting in
English: https://www.medincell.com/en/investors/#events_
The company's management will answer shareholders' questions,
which can be sent to communication@medincell.com, or asked live
during the video conference.
About MedinCell
MedinCell is a clinical- and commercial-stage biopharmaceutical
company developing long-acting injectable drugs in many therapeutic
areas. Our innovative treatments aim to guarantee compliance with
medical prescriptions, to improve the effectiveness and
accessibility of medicines, and to reduce their environmental
footprint. They combine already known and used active ingredients
with our proprietary BEPO® technology which controls the delivery
of a drug at a therapeutic level for several days, weeks or months
from the subcutaneous or local injection of a simple deposit of a
few millimeters, entirely bioresorbable. The first treatment based
on BEPO technology, intended for the treatment of schizophrenia,
was approved by the FDA in April 2023, and is now distributed in
the United States by Teva under the name UZEDY™ (BEPO technology is
licensed to Teva under the name SteadyTeq™).
We collaborate with leading pharmaceutical companies and
foundations to improve global health through new treatment options.
Based in Montpellier, MedinCell currently employs more than 140
people representing more than 25 different nationalities.
UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals
www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231211988766/en/
David Heuzé - Head of Communications
david.heuze@medincell.com / +33 (0)6 83 25 21 86
Media Relations Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94
Investor Relations France Louis-Victor
Delouvrier/Alban Dufumier medincell@newcap.eu / +33 (0)1 44 71
94 94
Head of US Financial Strategy & IR Grace Kim
grace.kim@medincell.com / +1 (646) 991-4023
Grafico Azioni Medincell (EU:MEDCL)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Medincell (EU:MEDCL)
Storico
Da Mag 2023 a Mag 2024
